Comparative study of the effectiveness of treating advanced NSCLC using docetaxel+lobaplatin and docetaxel+cisplatin regimens with concurrent radiotherapy
WU Jing
LIU Yanping
LONG Zhixiong
ZHANG Jiangzhou
GAO Xia
TAO Dan
HUANG Hui
HUANG Yali
ZHANG Liqiong
HUANG Ying
Abstract：Objective To compare the clinical effectiveness and adverse reactions of treating a NSCLC using docetaxel+lobaplatin ( DL) and docetaxel+cisplatin ( DP ) regimens with concurrent radiotherapy. Methods Sixty-four patients with phase Ⅲor phase Ⅳ without operation options, were randomly assigned to two groups for DL or DP regimen. The DL regimen ( 32 cases) involved chemotherapy of docetaxel 75 mg/m2 on day 1, iv drip;lobaplatin 30 mg/m2 on day 1, iv drip, and radiation therapy beginning on day 1, three dimensional conformal radiotherapy or intensity modula-ted radiation therapy gross tumor volume 2. 00—2. 12 Gy/d, with a total dosage of 60—74 Gy/30—35 F. The DP regimen involved chemotherapy of docetaxel 75 mg/m2 on day 1, iv drip, cisplatin 25 mg/m2 day 1 through day 3, iv drip;and radiotherapy in the same with DL regimen. Results The DL regimen achieved complete remission ( CR) of 9. 7﹪, partial remission ( PR) of 64. 5﹪, stable disease ( SD) of 16. 1﹪ and progression disease ( PD) of 9. 7﹪. The DP regimen achieved CR of 6. 2﹪, PR of 71. 9﹪, SD of 12. 5﹪ and PD of 9. 4﹪. The effectiveness for DL and DP regimen was 74. 2﹪ and 78. 1﹪ respectively. The one-year and two-year survival rate were 74. 2﹪ and 50. 0﹪ for DL regimen, 75. 0﹪ and 45. 5﹪ for DP regimen respectively. The comparison showed no difference of statistical significance ( P>0. 05) between the DL and DP regimens. The main adverse reactions included myelosuppression, gastrointestinal reaction, radioactive esophagitis and radiation pneumonitis. The white blood cells and platelets decreased by 29. 0﹪ and 16. 1﹪ for phase Ⅲ re-spectively, 25. 0﹪ and 6. 2﹪ respectively for phase iv, both bearing no significant difference ( P>0. 05) . The digestive tract reaction rates were 3. 2﹪ and 28. 1﹪ for phaseⅢand phaseⅣrespec-tively, bearing a significant difference (P=0. 007). The radiation esophagitis and pneumonitis in two groups showed no significant difference ( P>0. 05) . Conclusion DL and DP regimens showed no significant difference in the effectivenes of treating NSCLC, with DP regimen resulting in more adverse reactions of digestive tract than the DL regimen.
Keywords：DocetaxelLobaplatinCisplatinNon-small-cell lung carcinoma ( NSCLC )RadiotherapyChemotherapyConcurrent chemo-radiotherapy
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 70-73 )